Serum trough infliximab levels: A comparison of three different immunoassays for the monitoring of CT-P13 (infliximab) treatment in patients with inflammatory bowel disease-Reference-Cited by-同舟云学术

Serum trough infliximab levels: A comparison of three different immunoassays for the monitoring of CT-P13 (infliximab) treatment in patients with inflammatory bowel disease

Published:2016-01 Issue:1 Volume:44 Page:33-36
ISSN:1045-1056
Container-title:Biologicals
language:en
Short-container-title:Biologicals

Author:

Malíčková Karin,Ďuricová Dana,Bortlík Martin,Hind’oš Miroslav,Machková Naděžda,Hrubá Veronika,Lukáš Martin,Zima Tomáš,Lukáš Milan

Publisher

Elsevier BV

Subject

Pharmacology,General Immunology and Microbiology,Applied Microbiology and Biotechnology,General Medicine,Bioengineering,Biotechnology

Reference17 articles.

1. Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases;Amiot;Ther Adv Gastroenterol,2015

2. Governing board and operational board of ECCO. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD);Danese;J Crohns Colitis,2013

3. Biosimilars in the therapy of inflammatory bowel diseases;Hlavaty;Eur J Gastroenterol Hepatol,2014

4. Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry;Beck;MAbs,2013

5. Future directions in inflammatory bowel disease management;D'Haens;J Crohns Colitis,2014

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of SB2-Infliximab With Originator-Infliximab in the Measurement of Serum Concentrations: A Short Communication;Therapeutic Drug Monitoring;2021-10

2. Comparison of three immunoassays for infliximab trough level monitoring in paediatric inflammatory bowel diseases;Biologicals;2021-04

3. Infliximab pharmacokinetics monitoring in inflammatory bowel disease;Vnitřní lékařství;2020-12-15

4. Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure;Alimentary Pharmacology & Therapeutics;2020-09-27

5. Infliximab in young paediatric IBD patients: it is all about the dosing;European Journal of Pediatrics;2020-08-19